Table 2.
Response to first-, second- and third-line of therapies and according to the type of first-line treatment
| CR | PR | SD | PD | ORR | DCR | |
|---|---|---|---|---|---|---|
| Response in different line of treatments | ||||||
| First line (n = 111) | 3 (2.7%) | 40 (36%) | 42 (37.8%) | 26 (23.4%) | 43 (38.7%) | 85 (76.6%) |
| Second line (n = 62) | 0 (0%) | 5 (8.1%) | 26 (41.9%) | 31 (50%) | 5 (8.1%) | 31 (50%) |
| Third line (n = 35) | 0 (0%) | 0 (0%) | 10 (28.6%) | 25 (71.4%) | 0 (0%) | 10 (28.6%) |
| Response according to the type of first-line treatment | ||||||
| Irinotecan-based chemotherapy doublet (n=29) | 0 (0%) | 10 (34.5%) | 11 (37.9%) | 8 (27.6%) | 10 (34.5%) | 21 (72.41%) |
| Oxaliplatin-based chemotherapy doublet (n=66) | 2 (3.0%) | 22 (33.3%) | 26 (39.4%) | 16 (24.2%) | 24 (36.36%) | 50 (75.75%) |
| Chemotherapy triplet (n=16) | 1 (6.3%) | 8 (50%) | 5 (31.3%) | 2 (12.5%) | 9 (56.25%) | 14 (87.5%) |
CR, complete response; DCR, disease response rate; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.